ABN Amro Investment Solutions Has $14.25 Million Stake in Intuitive Surgical, Inc. $ISRG

ABN Amro Investment Solutions increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 158.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 25,156 shares of the medical equipment provider’s stock after acquiring an additional 15,429 shares during the period. ABN Amro Investment Solutions’ holdings in Intuitive Surgical were worth $14,247,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. BlueStem Wealth Partners LLC increased its holdings in shares of Intuitive Surgical by 2.9% during the 4th quarter. BlueStem Wealth Partners LLC now owns 1,042 shares of the medical equipment provider’s stock valued at $590,000 after acquiring an additional 29 shares during the last quarter. Midwest Professional Planners LTD. increased its holdings in shares of Intuitive Surgical by 1.8% during the 4th quarter. Midwest Professional Planners LTD. now owns 2,797 shares of the medical equipment provider’s stock valued at $1,584,000 after acquiring an additional 49 shares during the last quarter. Northbridge Financial Group LLC acquired a new position in shares of Intuitive Surgical during the 4th quarter valued at about $1,376,000. Atle Fund Management AB increased its holdings in shares of Intuitive Surgical by 13.3% during the 4th quarter. Atle Fund Management AB now owns 22,322 shares of the medical equipment provider’s stock valued at $12,642,000 after acquiring an additional 2,615 shares during the last quarter. Finally, Intrust Bank NA increased its holdings in shares of Intuitive Surgical by 4.9% during the 4th quarter. Intrust Bank NA now owns 7,359 shares of the medical equipment provider’s stock valued at $4,168,000 after acquiring an additional 347 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In other news, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $446.95, for a total transaction of $178,780.00. Following the sale, the executive vice president owned 6,120 shares of the company’s stock, valued at approximately $2,735,334. This trade represents a 6.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark Brosius sold 645 shares of Intuitive Surgical stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $485.01, for a total value of $312,831.45. Following the sale, the senior vice president directly owned 1,613 shares in the company, valued at $782,321.13. The trade was a 28.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 5,683 shares of company stock worth $2,775,891 in the last three months. Company insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ISRG shares. Truist Financial lowered their price objective on Intuitive Surgical from $650.00 to $580.00 and set a “buy” rating on the stock in a report on Wednesday, April 15th. JPMorgan Chase & Co. lowered their target price on Intuitive Surgical from $625.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Piper Sandler dropped their price target on Intuitive Surgical from $620.00 to $580.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 22nd. Sanford C. Bernstein lifted their price target on Intuitive Surgical from $740.00 to $750.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Finally, Barclays set a $651.00 price target on Intuitive Surgical and gave the stock an “overweight” rating in a research report on Thursday, April 23rd. Nineteen analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $579.33.

Intuitive Surgical Stock Up 1.7%

Shares of NASDAQ ISRG opened at $449.03 on Thursday. The business’s 50 day moving average is $460.63 and its two-hundred day moving average is $511.79. The company has a market cap of $159.03 billion, a P/E ratio of 54.43, a P/E/G ratio of 3.53 and a beta of 1.51. Intuitive Surgical, Inc. has a 12 month low of $417.74 and a 12 month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.42. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.62 billion. During the same quarter last year, the firm earned $1.81 EPS. Intuitive Surgical’s revenue for the quarter was up 23.0% compared to the same quarter last year. Sell-side analysts expect that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.